Overview
- Shares crossed the $1 trillion threshold on Friday after a rally of more than 35% this year.
- In Q3, Lilly posted $17.6 billion in revenue, with $10.09 billion from its diabetes and obesity portfolio.
- Wall Street raised targets—Truist to $1,182 and JPMorgan to $1,150—citing sustained demand and pipeline momentum.
- Investors are watching oral candidate orforglipron, with Lilly indicating obesity submissions by year-end and analysts projecting possible approval next year.
- Lilly struck a White House pricing deal and outlined production expansions, moves that could widen access and support growth.